The mRNA expression and histological integrity in rat forebrain motor and sensory regions are minimally affected by acrylamide exposure through drinking water

Toxicology and Applied Pharmacology

Volumn 240, Issue 3, 2009, Pages 401-411

  Bowyer, John F ^a   Latendresse, John R ^b   Delongchamp, Robert R ^c   Warbritton, Alan R ^b   Thomas, Monzy ^a   Divine, Becky ^b   Doerge, Daniel R ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Pathology Associates International   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acrylamide; Basal ganglia; Dopamine; Gene expression; Neurotoxicity

Indexed keywords

ACRYLAMIDE; DRINKING WATER; SEROTONIN 1B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; DNA MICROARRAY; FOREBRAIN; GABAERGIC TRANSMISSION; GENE EXPRESSION; HISTOPATHOLOGY; LOCOMOTION; MOTOR CORTEX; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEOTIDE SEQUENCE; PARIETAL LOBE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY CORTEX; SUBSTANTIA NIGRA; UNINDEXED SEQUENCE; WATER CONTAMINATION; WEIGHT REDUCTION;

ACRYLAMIDE; ANIMALS; DNA, COMPLEMENTARY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSENCEPHALON; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; WATER SUPPLY;

RATTUS;

EID: 70349952433     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.036     Document Type: Article

References (83)

1. Ali S.F. Acrylamide-induced changes in the monoamines and their acid metabolites in different regions of the rat brain. Toxicol. Lett. 17 (1983) 101-105
2. Ali S.F., Hong J.S., Wilson W.E., Uphouse L.L., and Bondy S.C. Effect of acrylamide on neurotransmitter metabolism and neuropeptide levels in several brain regions and upon circulating hormones. Arch. Toxicol. 52 (1983) 35-43
3. Axelrod J. The metabolism of catecholamines in vivo and in vitro. Pharmacol. Rev. 11 (1959) 402-408
4. Axelrod J., and Laroche M.J. Inhibitor of O-methylation of epinephrine and norepinephrine in vitro and in vivo. Science 130 (1959) 800
5. Baker S.N. Oscillatory interactions between sensorimotor cortex and the periphery. Curr. Opin. Neurobiol. 17 (2007) 649-655
6. Barber D.S., Hunt J., LoPachin R.M., and Ehrich M. Determination of acrylamide and glycidamide in rat plasma by reversed-phase high performance liquid chromatography. J. Chromatogr., B, Biomed. Sci. Appl. 758 (2001) 289-293
7. Barber D.S., Hunt J.R., Ehrich M.F., Lehning E.J., and LoPachin R.M. Metabolism, toxicokinetics and hemoglobin adduct formation in rats following subacute and subchronic acrylamide dosing. Neurotoxicology 22 (2001) 341-353
8. Barlow B.K., Cory-Slechta D.A., Richfield E.K., and Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod. Toxicol. 23 (2007) 457-470
9. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57 (1995) 289-300
10. Bondy S.C., Tilson H.A., and Agrawal A.K. Neurotransmitter receptors in brain regions of acrylamide-treated rats. II: Effects of extended exposure to acrylamide. Pharmacol. Biochem. Behav. 14 (1981) 533-537
11. Bowyer J.F., and Schmued L.C. Fluoro-Ruby labeling prior to an amphetamine neurotoxic insult shows a definitive massive loss of dopaminergic terminals and axons in the caudate-putamen. Brain Res. 1075 (2006) 236-239
12. Bowyer J.F., Peterson S.L., Rountree R.L., Tor-Agbidye J., and Wang G.J. Neuronal degeneration in rat forebrain resulting from d-amphetamine-induced convulsions is dependent on seizure severity and age. Brain Res. 809 (1998) 77-90
13. Bowyer J.F., Pogge A.R., Delongchamp R.R., O'Callaghan J.P., Patel K.M., Vrana K.E., and Freeman W.M. A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes. Neuroscience 144 1 (2007) 66-76
14. Bowyer J.F., Latendresse J.R., Delongchamp R.R., Muskhelishvili L., Warbritton A.R., Thomas M., Tareke E., McDaniel L.P., and Doerge D.R. The effects of subchronic acrylamide exposure on gene expression, neurochemistry, hormones, and histopathology in the hypothalamus-pituitary-thyroid axis of male Fischer 344 rats. Toxicol. Appl. Pharmacol. 230 (2008) 208-215
15. Carlsson A. Some aspects of dopamine in the central nervous system. Adv. Neurol. 5 (1974) 59-68
16. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu. Rev. Neurosci. 10 (1987) 19-40
17. Chomczynski P., and Mackey K. Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques 19 (1995) 942-945
18. Crofton K.M., Padilla S., Tilson H.A., Anthony D.C., Raymer J.H., and MacPhail R.C. The impact of dose rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Toxicol. Appl. Pharmacol. 139 (1996) 163-176
19. Delongchamp R.R., Bowyer J.F., Chen J.J., and Kodell R.L. Multiple-testing strategy for analyzing cDNA array data on gene expression. Biometrics 60 (2004) 774-782
20. Delongchamp R.R., Velasco C., Razzaghi M., Harris A., and Casciano D. Median-of-subsets normalization of intensities for cDNA array data. DNA Cell Biol. 23 (2004) 653-659
21. Delongchamp R.R., Velasco C., Dial S., and Harris A.J. Genome-wide estimation of gender differences in the gene expression of human livers: statistical design and analysis. BMC Bioinformatics 6 Suppl. 2 (2005) S13
22. Delongchamp R.R., Velasco C., Desai V., Lee T., and Fuscoe J. Designing toxicogenomics studies that use cDNA array technology. Bioinformatics Biol. Insights 2 (2008) 323-334
23. Fendrick S.E., Xue Q.S., and Streit W.J. Formation of multinucleated giant cells and microglial degeneration in rats expressing a mutant Cu/Zn superoxide dismutase gene. J. Neuroinflammation 4 (2007) 9
24. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., and Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 681-698
25. Fleming S.M., and Chesselet M.F. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav. Pharmacol. 17 (2006) 383-391
26. Freeman, W. M., Robertson, D. J., and Vrana, K. E. (2000). Fundamentals of DNA hybridization arrays for gene expression analysis. Biotechniques 29, 1042-1046, 1048-1055.
27. Galvan A., and Wichmann T. GABAergic circuits in the basal ganglia and movement disorders. Prog. Brain Res. 160 (2007) 287-312
28. Gerfen C.R. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311 (1984) 461-464
29. Gerfen C.R. Functional organization of the striatum: relevance to actions of psychostimulant drugs of abuse. NIDA Res. Monogr. 125 (1993) 82-91
30. Gold B.G., Griffin J.W., and Price D.L. Somatofugal axonal atrophy precedes development of axonal degeneration in acrylamide neuropathy. Arch. Toxicol. 66 (1992) 57-66
31. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13 (1990) 244-254
32. Greenamyre J.T., Betarbet R., and Sherer T.B. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat. Disord. 9 Suppl. 2 (2003) S59-S64
33. Hagmar L., Tornqvist M., Nordander C., Rosen I., Bruze M., Kautiainen A., Magnusson A.L., Malmberg B., Aprea P., Granath F., and Axmon A. Health effects of occupational exposure to acrylamide using hemoglobin adducts as biomarkers of internal dose. Scand. J. Work, Environ. Health 27 (2001) 219-226
34. Harry G.J., Morell P., and Bouldin T.W. Acrylamide exposure preferentially impairs axonal transport of glycoproteins in myelinated axons. J. Neurosci. Res. 31 (1992) 554-560
35. Hess A., Desiderio C., and McAuliffe W.G. Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies. J. Neurocytol. 19 (1990) 338-342
36. Hopkins K.J., Wang G., and Schmued L.C. Temporal progression of kainic acid induced neuronal and myelin degeneration in the rat forebrain. Brain Res. 864 (2000) 69-80
37. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia-normal and in Parkinson's disease. J. Chem. Neuroanat. 22 (2001) 3-12
38. Jones E.G. Thalamic circuitry and thalamocortical synchrony. Philos. Trans. R. Soc. Lond., B Biol. Sci. 357 (2002) 1659-1673
39. Jones E.G. Thalamic organization and function after Cajal. Prog. Brain Res. 136 (2002) 333-357
40. Kopin I.J. Monoamine oxidase and catecholamine metabolism. J. Neural Transm. Suppl. 41 (1994) 57-67
41. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
42. Lehning E.J., Balaban C.D., Ross J.F., and LoPachin R.M. Acrylamide neuropathy. III. Spatiotemporal characteristics of nerve cell damage in forebrain. Neurotoxicology 24 (2003) 125-136
43. LoPachin R.M., Schwarcz A.I., Gaughan C.L., Mansukhani S., and Das S. In vivo and in vitro effects of acrylamide on synaptosomal neurotransmitter uptake and release. Neurotoxicology 25 (2004) 349-363
44. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) method. Methods 25 (2001) 402-408
45. Lobsiger C.S., and Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 10 (2007) 1355-1360
46. Lorang D., Amara S.G., and Simerly R.B. Cell-type-specific expression of catecholamine transporters in the rat brain. J. Neurosci. 14 (1994) 4903-4914
47. Ludolph A.C., He F., Spencer P.S., Hammerstad J., and Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18 (1991) 492-498
48. Mora F., Segovia G., and Del Arco A. Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Res. Rev. 58 2 (2008) 340-353
49. Morelli M., Di Paolo T., Wardas J., Calon F., Xiao D., and Schwarzschild M.A. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 83 (2007) 293-309
50. Nagatsu T., Levitt M., and Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 239 (1964) 2910-2917
51. Padilla S., Atkinson M.B., and Breuer A.C. Direct measurement of fast axonal organelle transport in the sciatic nerve of rats treated with acrylamide. J. Toxicol. Environ. Health 39 (1993) 429-445
52. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1995), Academic Press, San Diego, CA
53. Perl D.P., and Olanow C.W. The neuropathology of manganese-induced Parkinsonism. J. Neuropathol. Exp. Neurol. 66 (2007) 675-682
54. Pisani A., Bernardi G., Ding J., and Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 30 (2007) 545-553
55. Price J.L. Thalamus (1995), Academic Press, San Diego
56. Quik M., Bordia T., and O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharmacol. 74 (2007) 1224-1234
57. Ramaswamy S., McBride J.L., and Kordower J.H. Animal models of Huntington's disease. Ilar J. 48 (2007) 356-373
58. Sato M., Chen C.C., Akiyama K., and Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol. Psychiatry 18 (1983) 429-440
59. Schiffmann S.N., Fisone G., Moresco R., Cunha R.A., and Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 83 (2007) 277-292
60. Schmued L.C. Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res. 974 (2003) 127-133
61. Schmued L.C., and Bowyer J.F. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 759 (1997) 135-140
62. Schmued L.C., Stowers C.C., Scallet A.C., and Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res. 1035 (2005) 24-31
63. Seiden L.S., and Sabol K.E. Neurotoxicity of methamphetamine-related drugs and cocaine. In: Chang L.W.A.R.S.D. (Ed). Handbook of Neurotoxicology (1995), Marcel Dekker, Inc., New York, Basel, Hong Kong 824-844
64. Sickles D.W., Brady S.T., Testino A., Friedman M.A., and Wrenn R.W. Direct effect of the neurotoxicant acrylamide on kinesin-based microtubule motility. J. Neurosci. Res. 46 (1996) 7-17
65. Sickles D.W., Stone J.D., and Friedman M.A. Fast axonal transport: a site of acrylamide neurotoxicity?. Neurotoxicology 23 (2002) 223-251
66. Sickles D.W., Sperry A.O., Testino A., and Friedman M. Acrylamide effects on kinesin-related proteins of the mitotic/meiotic spindle. Toxicol. Appl. Pharmacol. 222 (2007) 111-121
67. Spencer P.S., and Schaumburg H.H. A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure. Can. J. Neurol. Sci. 1 (1974) 143-150
68. Spencer P.S., and Schaumburg H.H. A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can. J. Neurol. Sci. 1 (1974) 152-169
69. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16 (2002) 1474-1476
70. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 96 (2006) 706-718
71. Storey J. A direct approach to false discovery rates. J. Royal Stat. Soc. B 64 (2002) 479-498
72. Streit W.J. An improved staining method for rat microglial cells using the lectin from Griffonia simplicifolia (GSA I-B4). J. Histochem. Cytochem. 38 (1990) 1683-1686
73. Streit W.J. The role of microglia in brain injury. Neurotoxicology 17 (1996) 671-678
74. Streit W.J. Microglia and the response to brain injury. Ernst Schering Res. Found. Workshop (2002) 11-24
75. Streit W.J. Microglial senescence: does the brain's immune system have an expiration date?. Trends Neurosci. 29 (2006) 506-510
76. Tareke E., Bowyer J.F., and Doerge D.R. Quantification of rat brain neurotransmitters and metabolites using liquid chromatography/electrospray tandem mass spectrometry and comparison with liquid chromatography/electrochemical detection. Rapid Commun. Mass Spectrom. 21 (2007) 3898-3904
77. Tepper J.M., and Lee C.R. GABAergic control of substantia nigra dopaminergic neurons. Prog. Brain Res. 160 (2007) 189-208
78. Thomas D.M., Francescutti-Verbeem D.M., Liu X., and Kuhn D.M. Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment-an oligonucleotide microarray approach. J. Neurochem. 88 (2004) 380-393
79. Tilson H.A., and Cabe P.K. The effects of acrylamide given acutely or in repeated doses on fore- and hindlimb function of rats. Toxicol. Appl. Pharmacol. 47 (1979) 253-260
80. Twaddle, N.C., Churchwell, M.I., McDaniel, L.P., Doerge, D.R., 2004. Autoclave sterilization produces acrylamide in rodent diets: implications for toxicity testing. J. Agric. Food. Chem. 52 (13), 4344-4349.
81. Wright G.W., and Simon R.M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19 (2003) 2448-2455
82. Young J.F., Luecke R.H., and Doerge D.R. Physiologically based pharmacokinetic/pharmacodynamic model for acrylamide and its metabolites in mice, rats, and humans. Chem. Res. Toxicol. 20 (2007) 388-399
83. Zilles K., and Wree A. Cortex: areal and laminar structure. In: Paxinos G. (Ed). The Rat Nervous System (1995), Academic Press, San Diego 649-685